Lantern Pharma Inc. (LTRN)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

0.81 on 9 Oct 2026

2 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$17.12M

Free cash flow

$15.68M

Return on equity

-262.0%

Return on capital

-217.4%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
12 May 2026	KEYSER D JEFFREY Director	Bought	$100.00K	106%
12 May 2026	Schalop Lee Troy Director	Bought	$100.00K	opened
13 Jun 2025	Fletcher Aaron G.L. 10% owner	Sold at will	$123.60K	44.5%
13 Jun 2025	Kreis Leslie W. 10% owner	Sold at will	$123.60K	44.5%
12 Jun 2025	Fletcher Aaron G.L. 10% owner	Sold at will	$204.99K	53.9%
12 Jun 2025	Kreis Leslie W. 10% owner	Sold at will	$204.99K	53.9%

41out of 100

Profitability 0

Financial strength 48

Growth n/a

Insiders 93

Strongest on insiders (93), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$200.00K

2 buys, 2 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan